切入千亿美元市场，破解百年镇痛难题，英矽智能提名AI发现的新型镇痛候选药物

TL;DR - Insilico Medicine nominated ISM9528, an AI-discovered, brain-penetrant, non-opioid oral pain drug, as a preclinical candidate. It targets a previously unlinked pain mechanism and showed promising efficacy, safety, and pharmacokinetics in animal studies.

• PandaOmics identified and prioritized the undisclosed “Target Z” using omics, literature, and multimodal data; knockout studies supported its role in pain.
• Chemistry42 generated and optimized ISM9528 for potency, selectivity, brain penetration, metabolic stability, and bioavailability.
• In rodent pain models, ISM9528 matched or outperformed pregabalin and showed longer-lasting analgesia than morphine in one intravenous study.
• The company reports wide safety margins in 28-day rat and dog studies and plans GLP toxicology in October 2026, followed by clinical trials in 2027.